Clicky

APELLIS PHARMACT.DL-0001(1JK) News

Date Title
Jul 3 Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing
Jul 1 Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
Jul 1 Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
May 9 Apellis Pharmaceuticals' Funding Gaps, Weak Syfovre Sales Cloud Outlook, BofA Says
May 9 Apellis price target lowered to $20 from $28 at Scotiabank
May 9 Apellis Pharmaceuticals downgraded by Raymond James due to ’added uncertainty’
May 9 Is Apellis Pharmaceuticals, Inc. (APLS) The Best Stock That Will Bounce Back?
May 8 Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
May 8 Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ...
May 8 Q1 2025 Apellis Pharmaceuticals Inc Earnings Call
May 7 Why Apellis Pharmaceuticals Wilted on Wednesday
May 7 Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
May 7 Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
May 7 Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
May 6 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 23 Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts
Feb 21 Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Feb 21 High Growth Tech Stocks In The United States To Watch
Feb 20 Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?
Feb 20 Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN